Managing Director Sangsoo Lee Increases Stake in WOOJUNG BIO via Open Market Purchase, Limited Impact on Shareholder Value

Managing Director Sangsoo Lee acquired 4,814 common shares of WOOJUNG BIO through open market purchases on June 5 and 9, 2026, increasing his stake from 0.05% to 0.08%.
This minor insider buying does not involve any capital change or dilution for the company and may signal management confidence, but the impact on stock price is limited.
[AI Summary]A small insider purchase with no dilution effects, indicating management confidence but with negligible impact on shareholder value due to the tiny stake increase.